According to filings with the U.S. Securities and Exchange Commission, Isomark Health is raising $2,650,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Fariba Assadi-Porter played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Isomark Health
Isomark has developed a patented, non-invasive technology that can be used to monitor personal health and disease states by measuring and analyzing isotopic biomarkers through exhaled CO2 samples. Isomarks technology can rapidly measure a patented set of breath biomarkers for detecting the presence of infection in as little as two hours after onset. Presently, 1.7 million hospital patients in the United States contract infections annually. More than 750,000 of those infections will lead to sepsis, resulting in more than 200,000 patient deaths and over $33 billion spent in treatment. In addition to its non-invasive nature, Isomarks technology also can provide near real-time results, in contrast to current diagnostic tests which require hours or days for laboratory analysis. This represents not only a significant health benefit to patients but also substantive cost savings to consumers, insurance companies, and healthcare providers.

To learn more about Isomark Health, visit http://isomark.com/

Contact:
Fariba Assadi-Porter, Chief Executive Officer
608-571-2609
https://www.linkedin.com/in/isomark/

SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved